Before submitting requests for PharmaCare coverage of ANY compound, pharmacists must ensure that the request complies with the Compounded Prescriptions Policy in Compounded Prescriptions — Section 5.13, PharmaCare Policy Manual. Any amounts paid out by PharmaCare for compounds that do not comply with this policy are subject to recovery.
On this page:
Press Ctrl+F to search a table for a compound. For exceptional coverage of a compound not listed here, please refer to the Compounded Prescriptions — Section 5.13, PharmaCare Policy Manual.
All compounds—whether a PharmaCare benefit or not—must be submitted in PharmaNet using the appropriate PIN.
If you are unsure which PIN to use for the prescribed compound or if the patient meets criteria, please contact the PharmaNet HelpDesk before submitting the claim on PharmaNet.
The table below establishes maximum fees for both eligible compounds and for compounds approved via Special Authority. The inclusion of a fee for a particular type of compound in the schedule below, therefore, does not necessarily confer coverage.
The table below establishes maximum fees for both benefit compounds and for compounds approved via Special Authority, which would otherwise be a non-benefit. The inclusion of a fee for a particular type of compound in the schedule below, therefore, does not necessarily confer benefit status.
Compound | Maximum Allowable Compounding Fee |
---|---|
Oral solutions | $20.00 |
Oral suspensions | $20.00 |
Capsules | $0.30 per capsule |
Suppositories | $40.00 for a minimum 10-day supply. Prescriptions for less than 10-day supply are prorated to maximum $4.00 per day. |
Oral lozenges | $40.00 for a minimum 10-day supply. Prescriptions for less than 10-day supply are prorated to maximum $4.00 per day. |
CADD injections | $20.00 |
Sterile IV, IM, SC injections | $20.00 |
Intrathecal injections | $40.00 |
Creams/ointments/lotions < or = 250 g/mL | $15.00 |
Creams/ointments/lotions > or = 251 g/mL | $20.00 |
Sterile eye drops, preservative free | $30.00 |
All eligible compound PINs have criteria. Additionally, compounds containing active ingredients that are subject to Special Authority will require Special Authority approval.
Eligible PINs index:
The maximum compounding fee for oral suspensions is $20 per compound. For the list of eligible bases, see below this table.
Oral suspensions | Compound criteria | Special Authority required | PIN |
---|---|---|---|
acetazolamide | Yes | No | 22123223 |
allopurinol | Yes | No | 22123307 |
alprazolam | Yes | No | 22123308 |
amiloride | Yes | No | 22123309 |
amiodarone | Yes | No | 22123310 |
amitriptyline | Yes | No | 22123224 |
aripiprazole | Yes | Yes | 22123272 |
atenolol | Yes | No | 22123225 |
azathioprine | Yes | No | 22123236 |
baclofen | Yes | No | 22123226 |
bisoprolol | Yes | No | 22123227 |
captopril | Yes | No | 22123228 |
carvedilol | Yes | Yes, except for Plan P | 22123265 |
cisapride | Yes | Yes | 22123195 |
citalopram | Yes | No | 22123229 |
clobazam | Yes | No | 22123230 |
clonazepam | Yes | No | 22123231 |
clonidine | Yes | No | 22123232 |
clozapine | Yes | No | 22123233 |
cyclobenzaprine | Yes | No | 22123234 |
dantrolene | Yes | No | 22123235 |
diazepam | Yes | No | 22123237 |
domperidone | Yes | No | 22123238 |
enalapril | Yes | No | 22123239 |
escitalopram | Yes | No | 22123240 |
esomeprazole | Yes | Yes | 22123271 |
felodipine | Yes | No | 22123241 |
folic acid | Yes | No | 22123242 |
gabapentin | Yes | Yes, only for Plan G | 22123243 |
glycopyrrolate | Yes | No | 22123302 |
griseofulvin | Yes | No | 22123244 |
hydrochlorothiazide | Yes | No | 22123245 |
hydroxyurea | Yes | Yes, only for Plan G | 22123270 |
hyoscine | Yes | No | 22123298 |
labetalol | Yes | No | 22123312 |
lamotrigine | Yes | No | 22123246 |
lansoprazole | Yes | Yes | 22123269 |
leflunomide | Yes | Yes | 22123273 |
levo-thyroxine | Yes | No | 22123247 |
lisinopril | Yes | No | 22123313 |
lorazepam | Yes | No | 22123248 |
methylphenidate | Yes | No | 22123249 |
metoprolol | Yes | No | 22123250 |
metronidazole | Yes | No | 22123251 |
nitrazepam | Yes | No | 22123314 |
nitrofurantoin | Yes | No | 22123252 |
nortriptyline | Yes | No | 22123253 |
omeprazole | Yes | Yes | 22123268 |
oxazepam | Yes | No | 22123254 |
pantoprazole sod | Yes | Yes | 22123315 |
paroxetine | Yes | No | 22123255 |
propranolol | Yes | No | 22123316 |
quetiapine | Yes | No | 22123257 |
ramipril | Yes | No | 22123256 |
rifampin | Yes | No | 22123317 |
sertraline | Yes | No | 22123258 |
sildenafil | Yes | Yes | 22123318 |
sotalol | Yes | No | 22123259 |
spironolactone | Yes | No | 22123260 |
sulfasalazine | Yes | No | 22123261 |
tacrolimus | Yes | No | 22123266 |
temazepam | Yes | No | 22123262 |
topiramate | Yes | No | 22123319 |
trazodone | Yes | No | 22123263 |
ursodiol | Yes | No | 22123264 |
vancomycin | Yes | Yes | 22123320 |
zopiclone | Yes | Yes | 22123274 |
Eligible bases for compounded oral suspensions include—but are not limited to—the following:
SF = sugar-free
* = either in-store made (stock solution) or commercially available product
If a vehicle or base is not listed above, please contact the PharmaNet Help Desk to determine whether the base is eligible for coverage before submitting a claim.
Note: Stock solutions are not eligible for a separate compound fee. Please see Maximum Allowable Costs and Fees, Stock Solutions.
Dermatological compounds may be processed under a PIN from the table below only if
Topical antifungals and retinoic acid also require a current Special Authority for the active ingredient, with the exception of an eligible topical antifungal for a Palliative Care registered patient (Plan P).
The maximum compounding fee for dermatologicals is $15 up to 250 gm/mL, and $20 over 250 gm/mL.
Dermatologicals | Compound criteria | Special Authority required | PIN |
---|---|---|---|
anthralin + salicyclic acid ointment (psoriasis/eczema) | Yes | No | 22123277 |
clindamycin in medicated/non-medicated benefit base | Yes | No | 22123280 |
coal tar/LCD in medicated/non-medicated benefit base | Yes | No | 22123305 |
corticosteroid in non-medicated benefit base | Yes | No | 22123283 |
corticosteroid in medicated benefit base | Yes | No | 22123303 |
corticosteroid + antifungal in benefit base | Yes | Yes, except for Plan P | 22123286 |
corticosteroid with at least one of the following: menthol, camphor, urea topical compound | Yes | No | 22123278 |
erythromycin in medicated/non-medicated benefit base | Yes | No | 22123279 |
metronidazole in medicated/non-medicated benefit base | Yes | No | 22123281 |
retinoic acid in medicated/non-medicated benefit base | Yes | Yes | 22123304 |
salicyclic acid ointment/cream (psoriasis/eczema) | Yes | No | 22123284 |
salicyclic acid + corticosteroid ointment/cream (psoriasis/eczema) | Yes | No | 22123285 |
sulfur/sulfacetamide in medicated benefit base | Yes | No | 22123282 |
urea (only in combination with at least one prescription benefit ingredient) | Yes | No | 22123337 |
Eligible non-medicated bases include—but are not limited to—the following:
​ For more information about eligible bases, please contact the PharmaNet Help Desk.
Mouth rinses | Special Authority required | PIN |
---|---|---|
corticosteroid with nystatin, diphenhydramine and tetracycline | Yes, except for Plan P registered patients | 22123332 |
corticosteroid with nystatin, diphenhydramine, tetracycline and lidocaine | Yes, except for Plan P registered patients | 22123333 |
corticosteroid with nystatin and diphenhydramine | Yes, except for Plan P registered patients or prescriptions written by an exempted prescriber. | 22123334 |
corticosteroid with nystatin and lidocaine, with or without glycerin | Yes, except for Plan P registered patients | 22123335 |
Repackaging a prescribed benefit injectable analgesic, or a Special Authority approved medication for intrathecal administration is only a benefit compound under a PIN from the table below when a patient is registered under the PharmaCare Palliative Care Drug Plan (Plan P).
Intrathecal Analgesics—Palliative | Compound criteria | Special Authority required | PIN |
---|---|---|---|
narcotic | Yes | No | 22123299 |
non-narcotic | Yes | No | 22123300 |
narcotic and non-narcotic | Yes | No | 22123301 |
Repackaging a prescribed injectable benefit analgesic into a continuous ambulatory delivery device (CADD) pump is only a benefit compound under a PIN from the table below when a patient is registered under the PharmaCare Palliative Care Drug Plan (Plan P).
CADD Injections—Palliative | Compound criteria | Special Authority required | PIN |
---|---|---|---|
non-narcotic | Yes | No | 22123287 |
narcotic | Yes | No | 22123288 |
controlled | Yes | No | 22123371 |
Medical Assistance in Dying (MAiD) | Special Authority required | PIN |
---|---|---|
phenobarbital/chloral hydrate/morphine sulphate suspension | No | 88000002 |
secobarbital suspension | No | 88000003 |
Preservative-free sterile eye drops may only be processed under a PIN from the table below when an ophthalmologist has documented the patient’s allergy to specified preservative(s) in commercially available eye drops on the compound prescription.
The maximum compounding fee for eye drops is $30.
Preservative-Free eyedrops | Compound criteria | Special Authority required | PIN |
---|---|---|---|
acetylcysteine | Yes | No | 22123289 |
amphotericin | Yes | No | 22123290 |
cefazolin | Yes | No | 22123291 |
ceftazidime | Yes | No | 22123292 |
gentamicin | Yes | No | 22123293 |
pilocarpine | Yes | No | 22123294 |
timolol | Yes | No | 22123295 |
tobramycin | Yes | No | 22123296 |
vancomycin | Yes | No | 22123297 |
Other compounds | Special Authority required | PIN |
---|---|---|
disulfiram 125 mg capsule | No | 66124089 |
disulfiram 250 mg capsule | No | 66124085 |
disulfiram 500 mg capsule | No | 66124087 |
prostaglandin injection | Yes | 66123910 |
papaverine in combination with phentolamine OR prostaglandin in combination with papaverine or phentolamine (BiMix) injection | Yes | 66123495 |
prostaglandin in combination with papaverine and phentolamine (TriMix) injection | Yes | 66123483 |
quinidine 200 mg capsule* | No | 66128429 |
saturated potassium iodide solution | No | 999113 |
* Coverage is provided for quinidine. Quinidine may be confused with clonidine, quinine.
For all non-benefit compounds, use the appropriate PINs in the table below.
If you are unsure whether a compound may be processed under an eligible PIN, please contact the PharmaNet HelpDesk before submitting the claim on PharmaNet.
Non-Benefit compounds | PIN |
---|---|
compound preparations (non-benefit) | 66123252 |
controlled compound (non-benefit) | 66124162 |
narcotic compound (non-benefit) | 66123367 |
topical anti-fungal compounded (non-benefit) | 66124164 |
hormone injection compound (non-benefit) | 66128214 |
hormone injection controlled compound (non-benefit) | 66128215 |
hormone oral compound (non-benefit) | 66128216 |
hormone oral controlled compound (non-benefit) | 66128217 |
hormone topical compound (non-benefit) | 66128218 |
hormone topical controlled compound (non-benefit) | 66128219 |
NSAID Topical compound (non-benefit) | 66128220 |
medicinal alcohol (non-benefit) | 66123239 |
All Purpose Nipple Ointment (APNO ) (mupirocin 2%, betamethasone 0.1%, miconazole 2% in ointment base) | 22123354 |
PharmaNet records show the following PINs are still being utilized to submit compound claims. Please refer to the Compounded Prescriptions Policy for eligibility requirements and the eligible PIN list for a suitable replacement.
If there isn’t an eligible PIN for the compound being prepared (where the patient meets the compound criteria) and there is no suitable non-benefit PIN from the table above, please contact the PharmaNet HelpDesk.
Discontinued compounds | PIN |
---|---|
narcotic compound (non-benefit) | 999776 |
compounded lotion | 842443 |
compounded ointment/cream | 842435 |
compounded mixture | 921297 |